Nuvation Bio Financial Results
Nuvation Bio reported third quarter 2026 financial results, highlighted by $45.0 million in total revenue and $27.5 million in net product revenue for its ROS1 inhibitor IBTROZI. The company ended the quarter with $663.4 million in cash and marketable securities while achieving market leadership in new patient starts for ROS1+ NSCLC.
“Just over one year after launch, IBTROZI was established as the market leader in advanced ROS1+ NSCLC, for both new patient starts and active patients across all lines of therapy combined, based on IQVIA claims data.”
David Hung, M.D., Founder, President, and Chief Executive Officer
“Our rapid rise to market leadership reflects growing provider confidence in IBTROZI’s durability of more than four years in TKI-naïve patients and a generally favorable safety profile that helps patients stay on therapy.”
David Hung, M.D., Founder, President, and Chief Executive Officer